Mitchell Cabisudo, MD
Child & Adolescent Psychiatry · New Windsor, NYNPI 1801055561
Payments from drug & device makers
Across 864 payments — averaging $400.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$241K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$95K
- Supernus Pharmaceuticals, Inc.$3K
- Johnson & Johnson$2K
- Alkermes, Inc.$1K
- Corium, LLC$582
- plus $3K from 19 others
What the payments were for
- Consulting fees$7,3002%
- Speaking & faculty fees$261,10075%
- Travel & lodging$59,69717%
- Food & beverage$18,0465%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 406 | $240,884 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 168 | $95,458 |
| Supernus Pharmaceuticals, Inc. | 15 | $2,745 |
| Johnson & Johnson | 42 | $2,190 |
| Alkermes, Inc. | 38 | $1,432 |
| Corium, LLC | 39 | $582 |
| Ironshore Pharmaceuticals Inc. | 23 | $493 |
| Otsuka America Pharmaceutical, Inc. | 26 | $481 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $316 |
| Sunovion Pharmaceuticals Inc. | 25 | $260 |
| Teva Pharmaceuticals USA, Inc. | 10 | $219 |
| Axsome Therapeutics, Inc. | 9 | $200 |
| Indivior Inc. | 10 | $173 |
| Neurocrine Biosciences, Inc. | 6 | $156 |
| Shire North American Group Inc | 7 | $121 |
| Bausch Health US, LLC | 5 | $101 |
| Neos Therapeutics, LP | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Orexo US, Inc. | 3 | $50 |
| Tris Pharma Inc | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Validus Pharmaceuticals LLC | 1 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Neuronetics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$346,209 in reported general payments places this provider in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 20 | $39,077 |
| Aripiprazole | 28 | $745 |
| Trazodone Hcl | 38 | $619 |
| Ziprasidone Hcl | 20 | $473 |
| Prazosin Hcl | 18 | $411 |
| Duloxetine Hcl | 40 | $370 |
| Clonazepam | 36 | $356 |
| Bupropion XlBupropion Hcl | 17 | $325 |
| Alprazolam | 37 | $282 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $231 |
| Sertraline Hcl | 14 | $219 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $186 |
| Lamotrigine | 35 | $128 |
| Escitalopram Oxalate | 15 | $94 |
| Fluoxetine Hcl | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $95,458 | $39,07720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in New Windsor
- Alexander KolevzonNew York$490K
- Jeffrey NewcornNew York$465K
- Matthew LorberNew York$398K
- Aleksandra DjukicBronx$332K
- Jeremy Veenstra-VanderweeleNew York$224K
- Parinda ParikhWhite Plains$185K
- John MarinoCanandaigua$70K
- Beth SmithBuffalo$65K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.